Kevin P. Starr - 16 Jun 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kevin P. Starr
Issuer symbol
SAGE
Transactions as of
16 Jun 2021
Net transactions value
+$999,983
Form type
4
Filing time
17 Jun 2021, 09:15:13 UTC
Previous filing
11 Jun 2021
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Purchase $999,983 +17,842 +5.9% $56.05 320,659 16 Jun 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $56.0447 USD to $56.9527 USD. The price reported above reflects the weighted average purchase price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.